The following trials provide information to treat various types of disease of the brain and the central and local nervous systems, both for ongoing and completed clinical trials. For more information on this therapy area please click here.
- collapse A Phase I, Open-label, Randomized, Balanced, Single-dose, Two-Part Study to Assess the Relative Bioavailability of NKTR-118 in Three Formulations under Fasted (3-Way crossover) and Fed (2-Way crossover) Conditions in Male and Non-fertile Female Subjects
- collapse A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of NKTR-118 Following Single and Multiple Ascending Oral Dose Administration in Healthy Young and Elderly Japanese Subjects, and an Open Randomized, Crossover Study to Investigate the Effect of Food on the Pharmacokinetics After Single Oral Doses of NKTR-118 in Healthy Male Japanese Subjects
- collapse A Study to Investigate the Analgesic Efficacy of AZD2423 Compared With Placebo
- collapse A Single Center, Randomized, Double-blinded, Placebo-controlled, Open-label, Positive-controlled, Four-way Crossover Study to Assess the Effect of a Single Oral Dose NKTR-118 Administration on QTc Interval Compared to Placebo, Using AVELOX (Moxifloxacin) as a Positive Control, in Healthy Male Subjects
- collapse Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4451
- collapse A Phase II, Multi-center, Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Pharmacodynamic Effect of Single and Multiple Oral Doses of AZD1446/ Placebo and a Single Dose of Donepezil on Quantified Electroencephalography and Event-Related Potentials in Patients With AD
- collapse A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Modified-Release Formulations of AZD1446 in Young and Elderly Healthy Japanese Volunteers After Oral Single and Repeated Doses
- collapse A Multicenter, open-label study using the MIDAS questionnaire to assess the effect of using the HCPC guidelines for migraine management in primary care, including the use of Zomig-ZMT (Zolmitriptan) orally disintegrating tablets 5.0mg and Zomig nasal spray 5.0mg as indicated.
- collapse CANADA - STACK
- collapse Canada - SPARK
